Reuters logo
BRIEF-Propanc Biopharma submits orphan drug designation request to FDA for treatment of ovarian cancer
October 25, 2017 / 12:43 PM / in 2 months

BRIEF-Propanc Biopharma submits orphan drug designation request to FDA for treatment of ovarian cancer

Oct 25 (Reuters) - Propanc Biopharma Inc-

* Propanc Biopharma submits orphan drug designation request to the US Food And Drug Administration for treatment of ovarian cancer Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below